Clinical trials
Combination Therapy clinical trials
Below are recruiting combination therapy clinical trials, each written for real people, not researchers. We’re tracking 894 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06552936Recruiting
Laser therapy for faster healing after tooth extraction
This study tests whether using a special laser after a lower-jaw tooth extraction can help the socket heal faster and grow new bone. It may benefit people who plan to get a dental implant later.
Lahore, Punjab ProvinceAges 21 years+ - NCT06557369Recruiting
New light therapy for intermediate age-related macular degeneration
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
BergamoAges 50 years+ - NCT06560112RecruitingPhase 2
Combination therapy trial for recurrent ovarian cancer
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
ShanghaiAges 18 years+ - NCT06567301Recruiting
Shockwave vs. special gel for knee osteoarthritis pain
This trial compares two treatments for knee osteoarthritis: a shockwave therapy and a gel containing chitosan nanoparticles (tiny particles) applied with ultrasound. It uses AI to detect changes in knee tissues. The goal is to find which treatment better reduces pain and improves function.
Giza, El DokkiAges 40–60 - NCT06640582RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced brain cancer
This trial tests a new treatment for advanced brain cancers like glioma and meningioma. It combines your own immune cells (tumor-infiltrating lymphocytes or TILs) with an immunotherapy drug (pembrolizumab) to help your body fight the tumor. It's for people who have tried other treatments without success or have no standard options left.
Beijing, Beijing MunicipalityAges 16–90 - NCT06647745RecruitingPhase 3
Study for type 2 diabetes and high blood pressure
This study tests a new combination of three medications (THP-00101, THP-00102, and THP-00103) for people with type 2 diabetes and essential high blood pressure. It aims to see if this combination is safe and effective compared to standard treatments.
SeoulAges 19 years+ - NCT06649162Recruiting
Fatty liver risk in type 2 diabetes and new combo therapy
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
Andong, Gyeongsangbuk-doAges 19 years+ - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT06655480RecruitingPhase 2
Triple drug therapy for advanced heart failure with preserved ejection fraction
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
MoscowAges 40–80 - NCT06684470RecruitingEarly Phase 1
Combining a low-FODMAP diet with medication for IBS-D
This trial tests if a special diet (low-FODMAP) combined with a medication (mirtazapine) can improve IBS with diarrhea symptoms. It is for adults who have not tried these treatments before.
Jacksonville, FloridaAges 18–70 - NCT06698965RecruitingPhase 2
Study of trilaciclib, envafolimab, etoposide, and carboplatin for extensive-stage small cell lung cancer
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07645222RecruitingPhase 1
Testing HS-20122 combined therapy for advanced lung cancer
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
Guangzhou, GuangdongAges 18–75 - NCT06735898Recruiting
A combined therapy for recovery after intensive care
This trial tests a combination of CYTOFLAVIN (given as an IV and later as a pill) to help people with long-term symptoms after spending time in the ICU. It aims to improve muscle weakness, breathing, swallowing, and energy levels during later stages of rehabilitation.
Yekaterinburg, Sverdlovsk OblastAges 18 years+ - NCT06764771RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
Hackensack, New JerseyAges 18 years+ - NCT06767345RecruitingPhase 4
Comparing two cholesterol medicines for plaque stabilization
This study compares two ways to lower cholesterol and stabilize artery plaque in people with coronary artery disease who are having a stent procedure. It tests whether a moderate statin plus ezetimibe works as well as a high-intensity statin alone for stabilizing plaque.
Seoul, SeoulAges 18 years+ - NCT06885710RecruitingPhase 1
T cell therapy with antivirals for chronic hepatitis B
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
ShanghaiAges 18–65 - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT06968962Recruiting
Starting PAH treatment: one drug first or two drugs together?
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
Hangzhou, ZhejiangAges 18–80 - NCT06992804RecruitingEarly Phase 1
Light therapy and lecanemab for mild Alzheimer's
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
BeijingAges 50–90 - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT07002177RecruitingPhase 1/Phase 2
Combination therapy study for ER+/HER2- breast cancer
This trial tests a new drug called FWD1802 combined with other treatments for people with a certain type of advanced breast cancer (ER-positive, HER2-negative). It aims to find better options if standard treatments have stopped working or aren't suitable.
ShanghaiAges 18–75 - NCT07018050RecruitingPhase 2
A study of a new combination for multiple myeloma
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
TianjinAges 18 years+ - NCT07026318Recruiting
Combining clot removal and tirofiban for stroke
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Combination Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for combination therapy?
- Yes. Clin2 currently lists 894 recruiting combination therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a combination therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a combination therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.